Abbott Q4 adj EPS $1.19, base organic +11%; FY24 guide $4.50-$4.70

ABBOTT LABORATORIES

2023-FY EPS reported $3.26 revenue$40,109,000,000

Q4 reported sales $10.241B (+1.5%); organic base business growth +11.0% excluding COVID tests.
GAAP diluted EPS $0.91; adjusted diluted EPS $1.19. Full-year 2023 adjusted EPS $4.44.
FY2024 guidance: GAAP EPS $3.20-$3.40, adjusted EPS $4.50-$4.70; organic sales growth 8-10% ex-COVID.
Medical Devices sales +17.5% reported; FreeStyle Libre revenue $1.4B (+23.8% organic).
Nutrition sales +12.2% reported, +13.9% organic; U.S. infant formula regained market-leading position.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ABBOTT LABORATORIES reported full-year 2024 results: EPS full-year adjusted diluted EPS of $4.50 to $4.70. Guidance initiated.

Period: full-year 2024
EPS: full-year adjusted diluted EPS of $4.50 to $4.70
Guidance: initiated
Result: guidance update

Exact text from the filing

Abbott issues full-year 2024 guidance for diluted EPS on a GAAP basis of $3.20 to $3.40 and full-year adjusted diluted EPS of $4.50 to $4.70.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.87

ABBOTT LABORATORIES reported the fourth quarter ended Dec. 31, 2023 results: EPS Fourth-quarter GAAP diluted EPS of $0.91 and adjusted diluted EPS of $1.19. Guidance initiated.

Period: the fourth quarter ended Dec. 31, 2023
EPS: Fourth-quarter GAAP diluted EPS of $0.91 and adjusted diluted EPS of $1.19
Guidance: initiated
Result: reported results

Exact text from the filing

On January 24, 2024, Abbott Laboratories announced its results of operations for the fourth quarter and full year 2023.

View on SEC.gov

Browse all earnings releases →

ABBOTT LABORATORIES filing history →

Source: SEC EDGAR

accession 0001628280-24-002009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.